9:30 am Evaluating Drug Safety Using Comprehensive Preclinical Assessments to Ensure Safer MASH Therapies
Time: 9:30 am
day: Conf day 2
Details:
- Employing comprehensive preclinical assessments so potential safety issues can be identified early in the drug development process to lead to safer MASH therapies for patients
- Utilizing a wide range of preclinical models and techniques to provide a thorough understanding of a drug’s potential toxicity profile to, minimize the risk of adverse events in clinical trials and improving patient outcomes
- Integrating advanced preclinical safety data with clinical trial design to enable the development of robust risk mitigation strategies to ensure the long-term safety and efficacy of MASH treatments
